Using targeted therapy to treat hereditary colorectal cancer by focusing on DNA mismatches
Targeting DNA Mismatches for Auger Electron Radiotherapy
This study is exploring a new way to treat hereditary colorectal cancer by using a special technology that targets and fixes mistakes in DNA that can cause tumors, which might make radiation therapy work better for patients with this condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hunter College NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10751210 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating hereditary colorectal cancer by targeting mismatched DNA base pairs that can lead to tumor development. The study utilizes a technology called metalloinsertors, which bind specifically to these mismatches and disrupt their formation, potentially enhancing the effectiveness of radiotherapy. By employing iodine-123, an Auger electron-emitting radionuclide, the research aims to develop a targeted radiotherapeutic that could selectively destroy cancer cells with DNA repair deficiencies. Patients with hereditary non-polyposis colorectal cancer may benefit from this innovative treatment strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with hereditary non-polyposis colorectal cancer or those with known mismatch repair deficiencies.
Not a fit: Patients without hereditary colorectal cancer or those whose cancer is not associated with DNA mismatch repair deficiencies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new targeted treatment option for patients with hereditary colorectal cancer, improving their outcomes.
How similar studies have performed: While the approach of using metalloinsertors is relatively novel, previous research has shown promise in targeting DNA mismatches for therapeutic purposes.
Where this research is happening
New York, United States
- Hunter College — New York, United States (Active)
Researchers
- Principal investigator: Zeglis, Brian Matthew — Hunter College
- Study coordinator: Zeglis, Brian Matthew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.